Results 51 to 60 of about 586,923 (192)

Incidence and risk factors of neonatal hypoglycemia after ritodrine therapy in premature labor: a retrospective cohort study

open access: yesJournal of Pharmaceutical Health Care and Sciences, 2019
Background Ritodrine hydrochloride (RD), a β2-adrenergic agonist, is widely used as a tocolytic medication to suppress premature labor, but can cause neonatal hypoglycemia, a potentially severe side effect.
Shoko Shimokawa   +7 more
doaj   +1 more source

Artemisinins [PDF]

open access: yes, 2005
Artemisinins were discovered to be highly effective antimalarial drugs shortly after the isolation of the parent artemisinin in 1971 in China. These compounds combine potent, rapid antimalarial activity with a wide therapeutic index and an absence of ...
Haynes, RK, Krishna, S, Woodrow, CJ
core   +2 more sources

Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2021
Quantitative assessment of drug‐drug interactions (DDIs) involving breast cancer resistance protein (BCRP) inhibition is challenged by overlapping substrate/inhibitor specificity.
Chester Costales   +9 more
doaj   +1 more source

Pharmacokinetics of Cephalexin after Intravenous and Single and Multiple Intramuscular Administration to Rabbit [PDF]

open access: yes, 2013
Cephalexin is a first generation cephalosporin widely used in rabbits. Its spectrum includes Pasteurella multocida and Staphylococcus aureus. These bacteria, together with Bordetella bronchiseptica, are the main cause of respiratory infections.
Albarellos, Gabriela Alejandra   +2 more
core   +2 more sources

Optimal designs for random effect models with correlated errors with applications in population pharmacokinetics [PDF]

open access: yes, 2009
We consider the problem of constructing optimal designs for population pharmacokinetics which use random effect models. It is common practice in the design of experiments in such studies to assume uncorrelated errors for each subject.
Dette, Holger   +2 more
core   +6 more sources

Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy

open access: yesPharmaceutics, 2020
Oxaliplatin (L-OHP) is widely prescribed for treating gastroenterological cancer. L-OHP-induced peripheral neuropathy is a critical toxic effect that limits the dosage of L-OHP. An ideal chemotherapeutic strategy that does not result in severe peripheral
Shinji Kobuchi, Risa Shimizu, Yukako Ito
doaj   +1 more source

A quantitative systems pharmacology approach to predict the safe‐equivalent dose of doxorubicin in patients with cardiovascular comorbidity

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2021
Patients with cardiovascular comorbidity are less tolerant to cardiotoxic drugs and should be treated with reduced doses to prevent cardiotoxicity. However, the safe‐equivalent dose of antitumor drugs in patients with cardiovascular disease/risk is ...
Lan Sang   +7 more
doaj   +1 more source

Cyclosporine Absorption Following Orthotopic Liver Transplantation [PDF]

open access: yes, 1986
Blood concentrations of cyclosporine were determined in adult and pediatric patients following orthotopic liver transplantation to quantitate cyclosporine blood clearance and oral absorption.
Beveridge   +20 more
core   +2 more sources

Pharmacokinetic–pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida [PDF]

open access: yes, 2018
A calf tissue cage model was used to study the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytetracycline in serum, inflamed (exudate) and noninflamed (transudate) tissue cage fluids.
Aliabadi   +45 more
core   +1 more source

Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure [PDF]

open access: yes, 1993
The single-dose pharmacokinetics of recombinant human erythropoietin (rHuEPO) given SC was investigated in 20 patients aged 7-20 years at different stages of chronic renal failure.
Braun, A.   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy